drugset
drugset / Trial / NCT00784524

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

NCT00784524 ↗

Phase 2 Terminated 14 enrolled Masonic Cancer Center, University of Minnesota
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Aldesleukin may stimulate the white blood cells to kill breast cancer cells. Giving vaccine therapy together with aldesleukin may be a more effective treatment for metastatic breast cancer. PURPOSE: This phase II trial is studying how well giving vaccine therapy together with aldesleukin works in treating women with metastatic breast cancer.

Timeline

Start
2008-09
Primary completion
2014-07
Completion
2014-07

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject LMI Vaccine 0.2 ml Intravenous
Subject aldesleukin Protein / enzyme biologic 1e+07 iu Subcutaneous

Indications

breast cancer